211 related articles for article (PubMed ID: 37999736)
1. The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review.
Lorkowski SW; Dermawan JK; Rubin BP
Virchows Arch; 2024 Feb; 484(2):369-375. PubMed ID: 37999736
[TBL] [Abstract][Full Text] [Related]
2. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
Dermawan JK; Rubin BP
Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
[TBL] [Abstract][Full Text] [Related]
3. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence.
Zhao Y; Pan Z; Namburi S; Pattison A; Posner A; Balachander S; Paisie CA; Reddi HV; Rueter J; Gill AJ; Fox S; Raghav KPS; Flynn WF; Tothill RW; Li S; Karuturi RKM; George J
EBioMedicine; 2020 Nov; 61():103030. PubMed ID: 33039710
[TBL] [Abstract][Full Text] [Related]
4. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
[TBL] [Abstract][Full Text] [Related]
5. New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges.
Ma W; Wu H; Chen Y; Xu H; Jiang J; Du B; Wan M; Ma X; Chen X; Lin L; Su X; Bao X; Shen Y; Xu N; Ruan J; Jiang H; Ding Y
Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38343328
[TBL] [Abstract][Full Text] [Related]
6. Overview of various techniques/platforms with critical evaluation of each.
Agwa E; Ma PC
Curr Treat Options Oncol; 2013 Dec; 14(4):623-33. PubMed ID: 24243164
[TBL] [Abstract][Full Text] [Related]
7. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.
Posner A; Prall OW; Sivakumaran T; Etemadamoghadam D; Thio N; Pattison A; Balachander S; Fisher K; Webb S; Wood C; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Wright G; Williams S; George J; Hicks RJ; Boussioutas A; Gill AJ; Solomon BJ; Xu H; Fellowes A; Fox SB; Schofield P; Bowtell D; Mileshkin L; Tothill RW
J Pathol; 2023 Jan; 259(1):81-92. PubMed ID: 36287571
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
[TBL] [Abstract][Full Text] [Related]
9. A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary.
Chen K; Zhang F; Yu X; Huang Z; Gong L; Xu Y; Li H; Yu S; Fan Y
J Transl Med; 2022 Apr; 20(1):158. PubMed ID: 35382836
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
[TBL] [Abstract][Full Text] [Related]
11. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
Rassy E; Pavlidis N
Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.
Zaun G; Borchert S; Metzenmacher M; Lueong S; Wiesweg M; Zaun Y; Pogorzelski M; Behrens F; Schildhaus HU; Virchow I; Kasper S; Schuler M; Theurer S; Liffers S
Eur J Cancer; 2024 Mar; 200():113540. PubMed ID: 38316065
[TBL] [Abstract][Full Text] [Related]
13. Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP).
Es HA; Mahdizadeh H; Asl AAH; Totonchi M
Sci Rep; 2021 Jul; 11(1):15112. PubMed ID: 34302033
[TBL] [Abstract][Full Text] [Related]
14. Cancer of Unknown Primary in the Molecular Era.
Kato S; Alsafar A; Walavalkar V; Hainsworth J; Kurzrock R
Trends Cancer; 2021 May; 7(5):465-477. PubMed ID: 33516660
[TBL] [Abstract][Full Text] [Related]
15. Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB; Federer-Gsponer J; Pauli C; Karapetyan AR; Chalabi N; Durán-Pacheco G; Beringer A; Bochtler T; Cook N; Höglander E; Jin DX; Losa F; Mileshkin L; Moch H; Ross JS; Sokol ES; Tothill RW; Krämer A
ESMO Open; 2023 Dec; 8(6):102035. PubMed ID: 37922692
[TBL] [Abstract][Full Text] [Related]
16. Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
Olivier T; Fernandez E; Labidi-Galy I; Dietrich PY; Rodriguez-Bravo V; Baciarello G; Fizazi K; Patrikidou A
Cancer Treat Rev; 2021 Jun; 97():102204. PubMed ID: 33866225
[TBL] [Abstract][Full Text] [Related]
17. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.
Greco FA
Curr Treat Options Oncol; 2013 Dec; 14(4):634-42. PubMed ID: 23990214
[TBL] [Abstract][Full Text] [Related]
18. Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
Weiss L; Heinrich K; Zhang D; Dorman K; Rühlmann K; Hasselmann K; Klauschen F; Kumbrink J; Jung A; Rudelius M; Mock A; Ormanns S; Kunz WG; Roessler D; Beyer G; Corradini S; Heinzerling L; Haas M; von Bergwelt-Baildon M; Boeck S; Heinemann V; Westphalen CB
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8225-8234. PubMed ID: 37062035
[TBL] [Abstract][Full Text] [Related]
19. Six-year experience of Australia's first dedicated cancer of unknown primary clinic.
van Mourik A; Tonkin-Hill G; O'Farrell J; Waller S; Tan L; Tothill RW; Bowtell D; Fox S; Fellowes A; Fedele C; Schofield P; Sivakumaran T; Wong HL; Mileshkin L
Br J Cancer; 2023 Aug; 129(2):301-308. PubMed ID: 37225894
[TBL] [Abstract][Full Text] [Related]
20. Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer.
Economopoulou P; Mountzios G; Pavlidis N; Pentheroudakis G
Cancer Treat Rev; 2015 Jul; 41(7):598-604. PubMed ID: 26033502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
